Teva Pharmaceutical Industries Ltd. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for pediatric Tourette syndrome. The submission, supported by positive Phase 3 data recently published in JAMA Neurology, marks a significant milestone in addressing a critical unmet need for patients. If approved, ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade.

Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer of Teva, emphasized the importance of the submission. "The NDA submission for ecopipam is a significant milestone for a potential first-in-class treatment option in pediatric Tourette syndrome," Hughes stated. He added that the development reflects the momentum in Teva's innovative pipeline and advances its Pivot to Growth strategy.

The Phase 3 study demonstrated that ecopipam significantly delayed time to relapse compared with placebo in pediatric patients who had achieved a clinical response during the open-label treatment period. The study met its primary efficacy endpoint, showing a statistically significant benefit for ecopipam over placebo (p = 0.008). The therapy was generally well tolerated during the trial.

Adverse events related to ecopipam therapy were reported in the study. The most common events included somnolence (n = 24 [11.1%]), anxiety (n = 21 [9.7%]), headache (n = 21 [9.7%]), insomnia (n = 19 [8.8%]), tic (n = 17 [7.9%]), and fatigue (n = 14 [6.5%]).

Ecopipam is a selective dopamine D1 receptor antagonist with a novel mechanism of action. It has received FDA Orphan Drug and Fast Track designations for the treatment of pediatric patients with Tourette syndrome. Orphan Drug designation is reserved for patient populations of 200,000 or fewer.

Tourette syndrome is a chronic neuro-developmental disorder characterized by involuntary motor and vocal tics, often beginning between ages 5 and 10. Despite existing treatments, many patients experience inadequate control or limiting side effects, highlighting the need for new therapeutic options.

Teva Pharmaceutical Industries Ltd. has acquired Emalex Biosciences for $700 million to strengthen its late-stage neuroscience pipeline with ecopipam. The acquisition advances Teva's Pivot to Growth strategy by adding a first-in-class selective dopamine D1 receptor antagonist designed to treat pediatric Tourette syndrome. The deal includes potential commercial milestone payments of up to $200 million and net sales-based royalties upon commercialization, subject to regulatory approval.

Paragon Biosciences, the creator of Emalex Biosciences, announced the closing of the sale, reinforcing its ability to build innovative biotechnology companies. Emalex was developed to address central nervous system disorders, following the success of other Paragon-founded companies such as Harmony Biosciences. Jeff Aronin, founder and CEO of Paragon Biosciences, stated that the transaction demonstrates the power of focused innovation to address underserved diseases.

Financial Details

The transaction structure includes an upfront payment and future contingent payments based on regulatory and commercial milestones.

Clinical Profile and Safety

Ecopipam has received Orphan Drug and Fast Track designations from the FDA. A U.S. New Drug Application (NDA) submission is anticipated in the second half of 2026. Phase 3 data for ecopipam were recently published in JAMA Neurology, demonstrating statistical significance for the primary efficacy endpoint compared to placebo (p = 0.0084).

The Phase 3 study evaluated time to relapse for pediatric patients stable and responding to ecopipam who were then randomized to ecopipam or placebo. Ecopipam was generally well-tolerated in the study. The most common adverse events related to ecopipam therapy were somnolence (10.2%), insomnia (7.4%), anxiety (6.0%), fatigue (5.6%), and headache (5.1%).

Richard Francis, President and Chief Executive Officer of Teva, stated that the acquisition reflects the company's strategy to advance its innovative pipeline through focused, capital-efficient business development. Eric Messner, chief executive officer of Emalex Biosciences, emphasized the team's focus on rigorous clinical execution and addressing a significant unmet need.